|
1. Biologie
|
|
|
High-Fat Diet May Fuel Spread of Prostate Cancer [NY Times]
|
|
|
|
|
|
When
prostate cancers lose a particular gene, they become tiny fat
factories, a team at Beth Israel Deaconess Medical Center in Boston
reported in a paper published in Nature Genetics. Then the cancers
spread from the prostate, often with deadly effect. Prostate cancers
that have not lost that gene also can spread, or metastasize — in mice,
at least — but only if they have a ready source of fat from the diet.
|
|
|
|
|
|
|
2.10 Etiologie - Alcool
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.1 Dép., diag. & prono. - Prostate
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
When You Need A Breast Screening, Should You Get A 3-D Mammogram? [KHN]
|
|
|
|
|
|
Overdiagnosis
is one of the potential downsides of this technology, said Dr. David
Grossman, chair of the U.S. Preventive Services Task Force. The more
sensitive test picks up more breast lesions for which the clinical
significance is unclear, potentially resulting in women receiving more
testing and treatment they don’t need. Some research suggests the biopsy
rate is slightly higher with 3-D mammograms.
|
|
|
|
|
|
|
5. Traitements
|
|
|
|
The Landscape of Kinase Inhibitors [In the Pipeline]
|
|
|
|
|
|
So
anyone who’s at all interested in the kinase inhibitor world needs to
look over this paper. And anyone who might want a reminder of (on one
side) just how messy and complex things are, or (on the other side) how
many interesting opportunities remain out there, should have a look,
too. This is state-of-the-art stuff.
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.12.10 Immunothérapies - Fusions et acquisitions
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
|
|
5.12.4 Immunothérapies - Essais
|
|
|
Merck Is Latest to Tout Success as Lung Cancer Drug Combos Plow Forward [Xconomy]
|
|
|
|
|
|
Merck
hasn’t, however, disclosed the magnitude of the benefit produced by the
combination. This information, to be shared at an unspecified future
medial meeting, is critical to help understand the benefits and risks of
taking the combination. As promising as new immunotherapies like
pembrolizumab have been, the side effects in combination with other
agents have been disconcerting, as Xconomy reported in 2017.
|
|
|
|
|
|
|
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
German drugmaker files $21.6M IPO for skin cancer drug [EndPoints]
|
|
|
|
|
|
The
company is the maker of Ameluz (aminolaevulinic acid), approved by the
FDA in combination with a medical device for the skin cancer precursor
actinic keratosis. Now, Biofrontera aims to expand its label so it can
be used in superficial basal cell carcinoma, a form of squamous cell
carcinoma called Bowen’s disease, and larger treatment areas of actinic
keratosis.
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
|
|
|
5.5 ASCO
|
|
|
|
Heads Up: 2018 ASCO GI Cancers Symposium [OBR]
|
|
|
|
|
|
Presentations
will include important studies on topics such as new way to detect
colorectal cancer early, novel surgical approaches for GI cancers, the
role of immunotherapy, and long-term evaluation of outcomes of patients
receiving standard therapy for colorectal cancer.
|
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.6 Publications
|
|
|
|